RNAi Technology Market
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) — The “RNAi Technology Market, By Application, By Geography – Size, Share, Outlook, and Opportunity Analysis, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
RNA based therapeutics have garnered significant attention in recent years due to its potential to treat a variety of disease such as cardiovascular disease, cancer, diabetes, TB, AIDS, as well as rare and genetic disorders. RNAi also has the potential to treat viral diseases such as those caused by the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Moreover, RNAi is now being used in biological and biomedical research to study the effect of blocking expression of a given gene.
Market Dynamics:
Increasing prevalence of chronic diseases, rise in focus on RNAi therapeutic development, rise in number of applications in molecular diagnostics, frequent approvals of RNAi therapeutics, and the outbreak of COVID-19 are major factors expected to drive growth of the global RNAi technology market over the forecast period.
For instance, in June 2022, Alnylam Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA, an RNAi therapeutic administered via subcutaneous injection once every three months for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Moreover, in August 2018, The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro, an RNAi therapeutic for individuals with a rare and deadly genetic disorder called hereditary transthyretin-mediated amyloidosis.
Key features of the study:
This report provides in-depth analysis of the global RNAi technology market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global RNAi technology market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Dicerna Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Arcturus Therapeutics, Ionis Pharmaceuticals Inc., Sigma Aldrich (Merck KGaA), Benitec Biopharma Ltd., Silence Therapeutics PLC, QIAGEN, SBI Biotech Co. Ltd., Alnylam Pharmaceuticals Inc., and Thermo Fisher Scientific Inc., among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market.
Detailed Segmentation:
Global RNAi Technology Market, By Application:
Drug Discovery and Development
Therapeutics
Global RNAi Technology Market, By Geography:
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Company Profiles:
QIAGEN
Dicerna Pharmaceuticals Inc.
Phio Pharmaceuticals Corp.
Arcturus Therapeutics
Ionis Pharmaceuticals Inc.
Sigma Aldrich (Merck KGaA)
Benitec Biopharma Ltd.
Silence Therapeutics PLC
SBI Biotech Co. Ltd.
Alnylam Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Key Topics Covered:
1. Research Objectives and Assumptions
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Global RNAi Technology Market – Impact of Coronavirus (Covid-19) Pandemic
5. Global RNAi Technology Market, By Application, 2017-2028, (US$ Mn)
6. Global RNAi Technology Market, By Geography, 2017-2028, (US$ Mn)
7. Competitive Landscape
8. Section
For more information about this report visit https://www.researchandmarkets.com/r/xo9iii
Attachment
RNAi Technology Market
Yesterday's report by Ontario's auditor general reveals what the Registered Nurses' Association of Ontario (RNAO) has said throughout the pandemic: the province's COVID-19 vaccine rollout was riddled with inequities, missed opportunities and waste. It also highlights the neglect that has characterized the government's approach to the nursing crisis with severe implications for Ontarians' health.
By Rachael Green, Benzinga
(Bloomberg) — OPEC’s efforts to deliver a substantial oil-output cut are being blunted the group’s allies.Most Read from BloombergMusk’s Neuralink Hopes to Implant Computer in Human Brain in Six MonthsBeverly Hills Cop Was California’s Highest-Paid Municipal WorkerAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatBlackstone’s $69 Billion Real Estate Fund Hits Redemption LimitMusk Suspends Ye From Twitter After Offensive Image PostThe Organization of Petroleum Ex
Tension flared over plans to take control of marketing and other decisions away from content chiefs at Disney.
And if you’re behind? It’s OK boomer. There’s still some time to catch up.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
OPEC+ is widely expected to stick to its latest target of reducing oil production by 2 million barrels per day (bpd) when it meets on Sunday, but some analysts believe that crude prices could fall if the group does not make further cuts. The Organization of the Petroleum Exporting Countries (OPEC) and allies led by Russia, a group known as OPEC+, has switched its planned in-person meeting in Vienna on Dec. 4 to a virtual one, which sources in the group say signals the likelihood of it leaving policy unchanged. The group agreed in early October to cut its oil production target by 2 million bpd from November until the end of 2023.
Horizon Therapeutics PLC is hitting the gas on its Montgomery County expansion — while considering buyout offers from larger pharmaceutical companies. Roughly a year since the Dublin company committed to building a research and development hub in Rockville and nearly two years after it acquired Gaithersburg’s Viela Bio Inc. for $3 billion, it is now deep into the construction of a facility at 9810 Darnestown Road. Horizon, a commercial-stage company developing treatments for rare, inflammatory and autoimmune diseases, says its planned 192,000-square-foot facility will include 60,000 square feet for laboratory space.
French oil giant TotalEnergies has become the first major North Sea operator to cut investment as a direct result of Rishi Sunak's windfall tax.
Before you open a retirement account, you should know the disadvantages of Roth IRAs, including income limits. Learn about the drawbacks of Roth IRAs.
Yahoo Finance's Julie Hyman breaks down leading business stories, including the FDA pausing authorization of Eli Lilly's COVID antibody drug, General Electric setting plans for its health care division, and Neuralink looking to test its brain chip on humans in six months.
In the hills of Tapairihua in Peru's Andes, Samuel Retamozo and other artisanal miners have found a rich seam of copper on their indigenous community's land. There's just one problem – the seam is within the site of Southern Copper Corp's planned $2.6 billion Los Chancas mine. One of the world's biggest copper miners, it also has a permit to dig in the same area.
Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.
But a bigger problem for Beijing may be the number of elderly Chinese who have yet to get their booster shots.
As healthcare costs continue to rise, more and more retailers are adding pharmacy and health services in new and creative ways. Heavy-hitting retailers like Walmart and Target have opened pharmacy departments to mixed results, while Dollar General's new CEO expressed interest in integrating healthcare services in its recent quarterly earnings call. Never a company to be left behind, Amazon has made moves to break into the healthcare industry.
(Bloomberg) — The world’s largest fertilizer firm is looking to do more in Brazil after a flurry of takeovers this year to bolster its retail presence within the South American nation.Most Read from BloombergMusk’s Neuralink Hopes to Implant Computer in Human Brain in Six MonthsBeverly Hills Cop Was California’s Highest-Paid Municipal WorkerAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatBlackstone’s $69 Billion Real Estate Fund Hits Redemption LimitMusk Suspe
(Bloomberg) — Saudi Arabia’s crude exports declined in November, as shipments to the US plunged to a multiyear low and flows to China slumped.Most Read from BloombergMusk’s Neuralink Hopes to Implant Computer in Human Brain in Six MonthsAn Arizona County’s Refusal to Certify Election Results Could Cost GOP a House SeatBeverly Hills Cop Was California’s Highest-Paid Municipal WorkerNew York, Singapore Are the World’s Most Expensive Cities Right NowStocks Churn After Big Rally With VIX Now Below
The attorneys general of California, Illinois and Washington D.C. asked a federal court on Thursday for a preliminary injunction that would prevent Albertsons Companies Inc, which is being purchased by rival Kroger Co, from paying a $4 billion dividend to shareholders. The state officials said in a court filing that Kroger, which does not yet own its rival, agreed with Albertsons that Albertsons would pay the dividend at the beginning of the merger review. "Payment of the special dividend, in conjunction with the restrictions defendants' merger agreement imposes on Albertsons' ability to borrow money, likely will hamper Albertsons' ability to compete with Kroger and other grocers, leaving shoppers facing higher prices, worse service, less innovation, closure of their local Safeway or other Albertsons supermarket, or all of the above," they said in the filing.
The leading warehouse club, Costco has 838 stores worldwide (at the end of fiscal 2022), with most sales derived in the United States (73%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but nearly 20% of paid members carry business memberships. Food and sundries accounted for nearly 39% of fiscal 2022 sales, with non-food merchandise 27%, warehouse ancillary and other businesses (such as fuel and pharmacy) 21%, and fresh food 13%. Costco’s warehouses average around 146,000 square feet; over 75% of its locations offer fuel. About 7% of Costco’s global sales come from e-commerce (excluding same-day grocery and various other services).
In a farewell column, Glenn Ruffenach considers how you know you’re ready to walk away, even if it’s hard to do.